Testing CX-5461 (Pidnarulex) for Metastatic Solid Cancers
This study is testing a drug called pidnarulex (CX-5461) in patients with solid cancers that have spread to other parts of the body (metastatic). The main goal is to see if pidnarulex causes a specific response in cancer cells called a Rad51 response, which helps understand how the drug works. Researchers will also look at the drug's safety, side effects, and how well it shrinks tumors. You would need to have a molecular test report showing your HRD (homologous recombination deficiency) mutation status to join. This study is currently unclear about its recruitment status and plans to enroll about 40 people.
- Study design
- This is an interventional study with no specified phase, planning to enroll 40 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would receive pidnarulex intravenously on days 1 and 8 of each 28-day cycle. You would also undergo CT scans, MRI scans, biopsies, and blood sample collections throughout the trial.
- Compensation
- Not stated in the trial record.
- Follow-up
- After treatment, you will be followed up at 30 days. The primary endpoint (Rad51 response) is measured for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06606990
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
Recruiting
PHASE1Ages 18+InterventionalTreatmentNational Cancer Institute (NCI)Government-funded
~40 participants
Updated 2026-09-16 on ClinicalTrials.gov
What's tested:Biopsy ProcedureBiospecimen CollectionComputed TomographyEchocardiography TestMagnetic Resonance ImagingPidnarulex
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
RAD51 response
Measured over Up to 3 years
Conditions
NCT06606990
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Marylandstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jibran Ahmed · PRINCIPAL_INVESTIGATOR · National Cancer Institute LAO
Who to contact
Site Public Contact
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients must have histologically confirmed solid tumors with metastatic disease that have progressed after ≥ 1 line of prior therapy and/or for whom no standard treatment is available that has been shown to improve survival.
Patients must have a molecular testing report to assess HRD mutation status prior to enrollment.
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) by chest x-ray or as ≥ 10 mm (≥ 1 cm) with CT scan, MRI, or calipers by clinical exam).
Patients must have a tumor site amenable to biopsy.
Age ≥ 18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥ 70%).
Absolute neutrophil count ≥ 1,500/mcL.
Hemoglobin ≥ 9 g/dL.
Platelets ≥ 100,000/mcL.
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
(However, patients with known Gilbert disease who have serum bilirubin level of up to 3 mg/dl may be enrolled).
International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 institutional upper limit of normal (ULN).
Subjects may receive supplementation to meet this eligibility criteria.
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \[SGPT\]) ≤ 3 x institutional ULN.
(AST and/or ALT ≤ 5 x ULN for patients with liver involvement).
Potassium ≥ lower limit of normal (LLN).
Subjects may receive supplementation to meet this eligibility criteria.
Magnesium ≥ LLN.
Subjects may receive supplementation to meet this eligibility criteria.
Ionized or corrected calcium ≥ LLN.
Subjects may receive supplementation to meet this eligibility criteria.
Creatinine ≤ 1.5 x institutional ULN OR creatinine clearance levels ≥ 60 ml/min based on the Cockcroft-Gault formula.
Oxygen (O2) saturation \> 90% on room air.
Prior standard or investigational therapy must have been completed ≥ 4 weeks or ≥ 5 half-lives of the prior agent (whichever is shorter) prior to enrollment; the exception is ≥ 2 weeks since any investigational agent administered (at a sub-therapeutic dose) as part of a phase 0 study.
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable.
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for ≥ 1 month after treatment of the brain metastases.
Patients with a prior or concurrent malignancy are eligible for this trial if, in the judgement of the principal investigator, the malignancy and its treatment do not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
The effects of pidnarulex on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) 14 days prior to study entry and for the duration of study participation and for at least 6 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women should not breastfeed while taking pidnarulex and for 6 months after cessation of treatment. Men treated or enrolled on this protocol must also agree to use adequate contraception 14 days prior to the study, for the duration of study participation, and 6 months after completion of pidnarulex administration.
Willingness to provide blood and biopsy samples for research purposes.
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion
Patients must have recovered from clinically-significant adverse-events of their most recent cancer immunotherapy to grade 1 or less (with the exception for alopecia or lymphopenia).
Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of pidnarulex will be determined based on their potential to interact with the CYP3A4 isozyme. Specifically, subjects taking strong CYP3A4 inhibitors or strong CYP3A4 inducers will be excluded from participation in the trial. A list of agents that interact with CYP450 isoenzymes is provided. For medications or substances not listed, or in cases of uncertainty, the principal investigator may consult with a medical expert or a pharmacologist to make an informed decision regarding eligibility.
History of allergic reactions attributed to inactive ingredients in the drug product.
Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous.
Pregnant and lactating women are excluded from this trial. The exclusion is based on the potential risk of adverse effects of pidnarulex on fetal development and newborn health. The safety of pidnarulex has not been established in pregnant or lactating women, and there is a possibility that the drug could cause harm to the developing fetus or be transferred to the infant through breast milk. Additionally, the physiological changes that occur during pregnancy and lactation could alter the pharmacokinetics and pharmacodynamics of pidnarulex, leading to unpredictable drug exposure and efficacy.
Patients with chronic, active HBV or HCV infections that require ongoing antiviral treatment will be excluded from the trial. This exclusion is due to the potential for drug interactions with the study medication and the risk of exacerbating liver disease.
Patients with cirrhosis, regardless of the etiology, will be excluded from participation in the trial. This is due to the increased risk of complications and adverse events associated with the study medication in this population.
Presence of known photosensitivity disorders (xeroderma pigmentosa, porphyria etc.). Patients who do not agree to use sunglasses and sun blocker (with sun protection factor 50 \[SPF50\] to ultraviolet B \[UVB\] and a high degree of protection against ultraviolet A \[UVA\]) if exposed to sunlight during the course of the study and for 3 months after the last dose are not eligible. Appropriate sunscreen products will be provided. Patients who plan to use sun beds or tanning booths during the course of the study and within 3 months after the last dose are not eligible.
Active ocular surface disease at baseline (based on ophthalmological evaluation).
History of cicatricial conjunctivitis (as evaluated by an ophthalmologist).
What this trial measures
- RAD51 responseUp to 3 years
Will be defined as at least 5 percent of cells with at least 5 positive foci per nucleus. Will target a 30% Rad51 response rate. Will be compared descriptively across the 2 cohorts, with and without homologous repair deficiency mutations.